Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression to First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
- Conditions
- Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-03-07
- Target Recruit Count
- 65
- Registration Number
- NCT06856213
- Locations
- 🇪🇸
Hospital Universitario Marqués de Valdecilla (Santander), Santander, Cantabria, Spain
🇪🇸Centro Oncológico de Galicia (La Coruña), A coruña, La Coruña, Spain
🇪🇸Hospital Infanta Leonor (Madrid), Vallecas, Madrid, Spain
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2025-03-13
- Target Recruit Count
- 34
- Registration Number
- NCT05784012
- Locations
- 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇪🇸Institut Catalá d'Oncologia (ICO) Hospitalet, Hospitalet de Llobregat, Cataluña, Spain
🇪🇸Institut Catalá d'Oncologia (ICO) BADALONA, Badalona, Cataluña, Spain
Spanish Study for Molecular Characterization of Thyroid Carcinoma
- Conditions
- Medullary Thyroid CarcinomaDifferentiated Thyroid Carcinoma
- Interventions
- Other: Immunohistochemistry (IHC)Other: Fluorescence In-Situ Hybridization (FISH)Other: Oncomine Focus Assay Platform with 52 genes
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-04-20
- Target Recruit Count
- 150
- Registration Number
- NCT04970134
- Locations
- 🇪🇸
Institut Català d'Oncologia Girona - ICO Girona, Girona, Spain
🇪🇸Hospital universitario Marqués de Valdecilla, Santander, Spain
🇪🇸Consorci Corporació Sanitària Parc Taulí de Sabadell, Sabadell, Barcelona, Spain
Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-03-23
- Target Recruit Count
- 531
- Registration Number
- NCT04672772
- Locations
- 🇪🇸
Hospital Universitario Canarias (TENERIFE), San Cristobal de la Laguna, Tenerife, Spain
🇪🇸Hospital Universitario Clínico San Carlos, Madrid, Spain
🇪🇸Hospital Regional Universitario de Málaga, Málaga, Andalucia, Spain
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)
- Conditions
- Head and Neck Cancer Stage IVRecurrent Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-01-09
- Target Recruit Count
- 141
- Registration Number
- NCT04282109
Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2021-01-07
- Target Recruit Count
- 17
- Registration Number
- NCT03887442
Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2019-04-16
- Target Recruit Count
- 40
- Registration Number
- NCT01264328
- Locations
- 🇪🇸
Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital de Navarra, Pamplona, Navarra, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- Drug: TPF, radiotherapy and cetuximabProcedure: H&N surgery
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2019-04-11
- Target Recruit Count
- 94
- Registration Number
- NCT00765011
- Locations
- 🇪🇸
Oncogranada, Granada, Spain
🇪🇸Hospital Dr.Josep Trueta (ICO Girona), Girona, Spain
🇪🇸Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain
TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.
- Conditions
- Head and Neck Cancer
- Interventions
- Other: TPF, radiotherapy and cetuximab.Other: TPF, radiotherapy and cisplatin.
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2019-05-24
- Target Recruit Count
- 519
- Registration Number
- NCT00716391
- Locations
- 🇪🇸
Hospital de Manresa, Manresa, Barcelona, Spain
🇪🇸Hospital Son Llàtzer, Palma De Mallorca, Mallorca, Spain
🇪🇸Hospital Son Dureta, Palma de Mallorca, Mallorca, Spain